Clinical review of 63 cases of sex cord stromal tumors

V. Zanagnolo, B. Pasinetti, E. Sartori

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Purpose of investigation: A retrospective analysis of 63 cases of sex cord stromal tumors treated in a 22-year period to evaluate the prognostic impact of different clinical parameters. Methods: Sixty-three cases of sex cord stromal tumors were studied. These neoplasms are characteristically detected at an early stage and may recur locally years after the initial diagnosis. The most frequent cell type was adult granulosa cell tumor (75%); a total of 37 patients (62%) had Stage IA lesions. Results: The cornerstone of treatment is surgery. Conservative surgical treatment was performed in 11 out of 47 cases (23%) of early stage tumor and in one of 13 patients affected by advanced neoplasm. Five of these 12 patients became pregnant after the treatment. Endometrial hyperplasia and uterine adenocarcinoma were diagnosed in 26.5% and 8.8% of the cases, respectively. Twenty-one patients (35%) received adjuvant therapy: 20 chemotherapy and one chemo-radiation treatment. Eight patients (13%) either progressed or recurred. All the recurrent patients but one had been treated with adjuvant chemotherapy (VAC and/or PVB). Overall survival by stage was 88.2% for Stage I and 30% for Stage III-IV. Conclusion: Tumor stage is the most important clinical parameter of prognostic relevance. Tumor size and laterality significantly affected prognosis in terms of overall survival; survival rate did not seem to be affected either by the age of the patients or by the modality of surgical treatment.

Original languageEnglish
Pages (from-to)431-438
Number of pages8
JournalEuropean Journal of Gynaecological Oncology
Volume25
Issue number4
Publication statusPublished - 2004

Fingerprint

Sex Cord-Gonadal Stromal Tumors
Neoplasms
Granulosa Cell Tumor
Endometrial Hyperplasia
Therapeutics
Survival
Adjuvant Chemotherapy
Adenocarcinoma
Survival Rate
Radiation
Drug Therapy

Keywords

  • Chemotherapy
  • Granulosa cell tumors
  • Sex cord stromal tumors
  • Surgical treatment

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Clinical review of 63 cases of sex cord stromal tumors. / Zanagnolo, V.; Pasinetti, B.; Sartori, E.

In: European Journal of Gynaecological Oncology, Vol. 25, No. 4, 2004, p. 431-438.

Research output: Contribution to journalArticle

Zanagnolo, V. ; Pasinetti, B. ; Sartori, E. / Clinical review of 63 cases of sex cord stromal tumors. In: European Journal of Gynaecological Oncology. 2004 ; Vol. 25, No. 4. pp. 431-438.
@article{5e375aa00987438191072153d50f123f,
title = "Clinical review of 63 cases of sex cord stromal tumors",
abstract = "Purpose of investigation: A retrospective analysis of 63 cases of sex cord stromal tumors treated in a 22-year period to evaluate the prognostic impact of different clinical parameters. Methods: Sixty-three cases of sex cord stromal tumors were studied. These neoplasms are characteristically detected at an early stage and may recur locally years after the initial diagnosis. The most frequent cell type was adult granulosa cell tumor (75{\%}); a total of 37 patients (62{\%}) had Stage IA lesions. Results: The cornerstone of treatment is surgery. Conservative surgical treatment was performed in 11 out of 47 cases (23{\%}) of early stage tumor and in one of 13 patients affected by advanced neoplasm. Five of these 12 patients became pregnant after the treatment. Endometrial hyperplasia and uterine adenocarcinoma were diagnosed in 26.5{\%} and 8.8{\%} of the cases, respectively. Twenty-one patients (35{\%}) received adjuvant therapy: 20 chemotherapy and one chemo-radiation treatment. Eight patients (13{\%}) either progressed or recurred. All the recurrent patients but one had been treated with adjuvant chemotherapy (VAC and/or PVB). Overall survival by stage was 88.2{\%} for Stage I and 30{\%} for Stage III-IV. Conclusion: Tumor stage is the most important clinical parameter of prognostic relevance. Tumor size and laterality significantly affected prognosis in terms of overall survival; survival rate did not seem to be affected either by the age of the patients or by the modality of surgical treatment.",
keywords = "Chemotherapy, Granulosa cell tumors, Sex cord stromal tumors, Surgical treatment",
author = "V. Zanagnolo and B. Pasinetti and E. Sartori",
year = "2004",
language = "English",
volume = "25",
pages = "431--438",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "4",

}

TY - JOUR

T1 - Clinical review of 63 cases of sex cord stromal tumors

AU - Zanagnolo, V.

AU - Pasinetti, B.

AU - Sartori, E.

PY - 2004

Y1 - 2004

N2 - Purpose of investigation: A retrospective analysis of 63 cases of sex cord stromal tumors treated in a 22-year period to evaluate the prognostic impact of different clinical parameters. Methods: Sixty-three cases of sex cord stromal tumors were studied. These neoplasms are characteristically detected at an early stage and may recur locally years after the initial diagnosis. The most frequent cell type was adult granulosa cell tumor (75%); a total of 37 patients (62%) had Stage IA lesions. Results: The cornerstone of treatment is surgery. Conservative surgical treatment was performed in 11 out of 47 cases (23%) of early stage tumor and in one of 13 patients affected by advanced neoplasm. Five of these 12 patients became pregnant after the treatment. Endometrial hyperplasia and uterine adenocarcinoma were diagnosed in 26.5% and 8.8% of the cases, respectively. Twenty-one patients (35%) received adjuvant therapy: 20 chemotherapy and one chemo-radiation treatment. Eight patients (13%) either progressed or recurred. All the recurrent patients but one had been treated with adjuvant chemotherapy (VAC and/or PVB). Overall survival by stage was 88.2% for Stage I and 30% for Stage III-IV. Conclusion: Tumor stage is the most important clinical parameter of prognostic relevance. Tumor size and laterality significantly affected prognosis in terms of overall survival; survival rate did not seem to be affected either by the age of the patients or by the modality of surgical treatment.

AB - Purpose of investigation: A retrospective analysis of 63 cases of sex cord stromal tumors treated in a 22-year period to evaluate the prognostic impact of different clinical parameters. Methods: Sixty-three cases of sex cord stromal tumors were studied. These neoplasms are characteristically detected at an early stage and may recur locally years after the initial diagnosis. The most frequent cell type was adult granulosa cell tumor (75%); a total of 37 patients (62%) had Stage IA lesions. Results: The cornerstone of treatment is surgery. Conservative surgical treatment was performed in 11 out of 47 cases (23%) of early stage tumor and in one of 13 patients affected by advanced neoplasm. Five of these 12 patients became pregnant after the treatment. Endometrial hyperplasia and uterine adenocarcinoma were diagnosed in 26.5% and 8.8% of the cases, respectively. Twenty-one patients (35%) received adjuvant therapy: 20 chemotherapy and one chemo-radiation treatment. Eight patients (13%) either progressed or recurred. All the recurrent patients but one had been treated with adjuvant chemotherapy (VAC and/or PVB). Overall survival by stage was 88.2% for Stage I and 30% for Stage III-IV. Conclusion: Tumor stage is the most important clinical parameter of prognostic relevance. Tumor size and laterality significantly affected prognosis in terms of overall survival; survival rate did not seem to be affected either by the age of the patients or by the modality of surgical treatment.

KW - Chemotherapy

KW - Granulosa cell tumors

KW - Sex cord stromal tumors

KW - Surgical treatment

UR - http://www.scopus.com/inward/record.url?scp=3242662815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242662815&partnerID=8YFLogxK

M3 - Article

C2 - 15285297

AN - SCOPUS:3242662815

VL - 25

SP - 431

EP - 438

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 4

ER -